Literature DB >> 19360228

[Yellow fever virus 17D neutralising antibodies in vaccinated Colombian people and unvaccinated ones having immunity against dengue].

Sergio Y Gómez1, Raquel E Ocazionez.   

Abstract

OBJECTIVE: Determining the frequency of yellow fever seroprotective antibody neutralising titres (YF-NT >or=1:10) in Colombians vaccinated with the 17 D virus and ascertaining the extent to which YF virus can be neutralised by dengue antibodies.
MATERIALS AND METHODS: Serum samples were taken from 100 subjects who showed their vaccination record and from 116 residents in municipalities (Norte de Santander) affected by a wild YF outbreak in 2002-2003 who were reported to have been YF vaccinated. Sera from individuals with (n=61) and without (n=16) dengue antibodies who had never been YF vaccinated were included. All the sera were tested by 75 % YF plaque-reduction neutralization test.
RESULTS: YF-NT titres >or=1:10 were founded in 90 % of subjects with vaccination recorded with minors variations in relation to age. In contrast, there was correlation between decrease of seroprotective YF-NT titres frequency and increase of immunization time (r=0.95; p=0.04). In residents in YF endemic area, YF-NT titres >or= 1.10 were founded in 92,6 % adults and 69 % children. YF 17 D virus was neutralized (52-100 %) by dengue sera more efficiently than non-dengue immune sera (p<0.001).
CONCLUSIONS: Individuals immunised with YF vaccine 17 D could not be protected against YF: up to 31% children and 10 % adults. Dengue antibodies inhibited YF virus and its significance in terms of YF protection must be investigated.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19360228     DOI: 10.1590/s0124-00642008000500012

Source DB:  PubMed          Journal:  Rev Salud Publica (Bogota)        ISSN: 0124-0064


  8 in total

Review 1.  Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years.

Authors:  Eduardo Gotuzzo; Sergio Yactayo; Erika Córdova
Journal:  Am J Trop Med Hyg       Date:  2013-09       Impact factor: 2.345

2.  Anamnestic immune response to dengue and decreased severity of yellow Fever.

Authors:  Ricardo O Izurieta; Maurizio Macaluso; Douglas M Watts; Robert B Tesh; Bolivar Guerra; Ligia M Cruz; Sagar Galwankar; Sten H Vermund
Journal:  J Glob Infect Dis       Date:  2009-07

3.  Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers.

Authors:  Nicole P Lindsey; Kalanthe A Horiuchi; Corey Fulton; Amanda J Panella; Olga I Kosoy; Jason O Velez; Elizabeth R Krow-Lucal; Marc Fischer; J Erin Staples
Journal:  J Travel Med       Date:  2018-01-01       Impact factor: 8.490

4.  Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil.

Authors:  Andréa Barbosa de Melo; Maria da Paz C da Silva; Maria Cecília F Magalhães; Laura Helena Vega Gonzales Gil; Eduardo M Freese de Carvalho; Ulisses M Braga-Neto; Giovani Rota Bertani; Ernesto T A Marques; Marli Tenório Cordeiro
Journal:  Am J Trop Med Hyg       Date:  2011-10       Impact factor: 2.345

5.  Prevalence and titers of yellow fever virus neutralizing antibodies in previously vaccinated adults.

Authors:  Karina Takesaki Miyaji; Vivian Iida Avelino-Silva; Marisol Simões; Marcos da Silva Freire; Carlos Roberto de Medeiros; Patrícia Emilia Braga; Maria Angélica Acalá Neves; Marta Heloisa Lopes; Esper Georges Kallas; Ana Marli Christovam Sartori
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2017-04-03       Impact factor: 1.846

Review 6.  Questions regarding the safety and duration of immunity following live yellow fever vaccination.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Expert Rev Vaccines       Date:  2016-06-20       Impact factor: 5.683

7.  Persistence of Neutralizing Antibody Responses Among Yellow Fever Virus 17D Vaccinees Living in a Nonendemic Setting.

Authors:  Bettie W Kareko; Brian L Booty; Chad D Nix; Zoe L Lyski; Mark K Slifka; Ian J Amanna; William B Messer
Journal:  J Infect Dis       Date:  2020-06-11       Impact factor: 7.759

8.  A Single 17D Yellow Fever Vaccination Provides Lifelong Immunity; Characterization of Yellow-Fever-Specific Neutralizing Antibody and T-Cell Responses after Vaccination.

Authors:  Rosanne W Wieten; Emile F F Jonker; Ester M M van Leeuwen; Ester B M Remmerswaal; Ineke J M Ten Berge; Adriëtte W de Visser; Perry J J van Genderen; Abraham Goorhuis; Leo G Visser; Martin P Grobusch; Godelieve J de Bree
Journal:  PLoS One       Date:  2016-03-15       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.